Eddy Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 16 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 M
- Revenue Growth %
- Profit Growth -5.56%
- Ebitda 50.00%
- Net Worth -1.31%
- Total Assets %
About Eddy Pharmaceuticals
Eddy Pharmaceuticals Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 July 2008 and has a history of 16 years and seven months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 M.
Satish Khanna, Dheeraj Chopra, and Naresh Batra serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233DL2008PTC180447
- Company No.
180447
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jul 2008
- Date of AGM
30 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Eddy Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satish Khanna  | Director | 03-Jul-2008 | Current |
| Dheeraj Chopra | Director | 03-Jul-2008 | Current |
| Naresh Batra | Director | 03-Jul-2008 | Current |
Financial Performance of Eddy Pharmaceuticals.
Eddy Pharmaceuticals Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 5.56% decrease in profit. The company's net worth dipped by a decrease of 1.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eddy Pharmaceuticals?
In 2019, Eddy Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.00 M
₹0
Charges Breakdown by Lending Institutions
- The Saraswat Cooperative Bank Limited : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Jun 2010 | The Saraswat Cooperative Bank Limited | ₹2.00 M | Open |
How Many Employees Work at Eddy Pharmaceuticals?
Unlock and access historical data on people associated with Eddy Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eddy Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eddy Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.